- Citations, last 5 years
- 520
- Works, last 5 years
- 36
- h-index
- 113
- Scientists listed
- 0
- Grants since 2016
- 51
Grants received
2024–2025 · contract · N01
TOXICOLOGY STUDIES IN MICE AND DOGS ADMINISTERED MTX-531
David L. Mccormick · IIT Research Institute · funded by National Institutes of Health
2024 · contract · N01
Contract Orientation and Kickoff Meeting
David L. Mccormick · IIT Research Institute · funded by National Institutes of Health
2024–2025 · contract · N01
TOXICOLOGY STUDIES IN RATS AND DOGS ADMINISTERED AIT-102
David Mccormick · IIT Research Institute · funded by National Institutes of Health
2024–2025 · contract · N01
IITRI - PERFORMANCE AREA 1 TO2
Michael O'Ryan · IIT Research Institute · funded by National Institutes of Health
2024–2025 · contract · N01
FIRST-IN-CLASS SMALL MOLECULE CANDIDATE NCGC72 (CD206 AGONIST) FOR IMMUNOLOGICALLY COLD SOLID ORGAN CANCERS
Thomas Horn · IIT Research Institute · funded by National Institutes of Health
2024–2025 · contract · N01
IITRI - NON-GLP DOSE RANGE FINDING (DRF) STUDIES-DEC. 2023 #2
Michael O'Ryan · IIT Research Institute · funded by National Institutes of Health
2024–2025 · contract · N01
IITRI - PTTP DRF BPN STUDY - TO3
Michael O'Ryan · IIT Research Institute · funded by National Institutes of Health
2024 · contract · N01
MTD-DRF STUDIES-TO 4
Michael O'Ryan · IIT Research Institute · funded by National Institutes of Health
2024–2025 · contract · N01
IITRI - PTTP DRF BPN STUDY - TO3
Michael O'Ryan · IIT Research Institute · funded by National Institutes of Health
2024–2025 · contract · N01
Toxicology Studies on Compound MTX-531
David L. Mccormick · IIT Research Institute · funded by National Institutes of Health
2024–2026 · contract · N01
IITRI - PERFORMANCE AREA 1 TO2
Michael O'Ryan · IIT Research Institute · funded by National Institutes of Health
2023–2024 · contract · N01
Base Title: PREVENT Preclinical Pharmacology and ToxicologyTask Order Title: Nicotine Reduction Therapy Using the Human Monoclonal Antibody ATI-1013
David Mccormick · IIT Research Institute · funded by National Institutes of Health
2022–2025 · contract · N01
PRECLINICAL TOXICOLOGY OF LARGE MOLECULE DRUGS DEVELOPED FOR CANCER AND OTHER INDICATIONS
David Mccormick · IIT Research Institute · funded by National Institutes of Health
2022–2029 · contract · N01
CONTRACT ORIENTATION & KICKOFF MEETING FOR R&D SERVICES UNDER "PRECLINICAL TOXICOLOGY OF SMALL MOLECULE DRUGS DEVELOPED FOR CANCER AND OTHER INDICATIO
David Mccormick · IIT Research Institute · funded by National Institutes of Health
2022–2023 · contract · N01
PRECLINICAL TOXICOLOGY OF LARGE MOLECULE DRUGS DEVELOPED FOR CANCER AND OTHER INDICATIONS
David Mccormick · IIT Research Institute · funded by National Institutes of Health
2022–2023 · contract · N01
PRECLINICAL TOXICOLOGY OF LARGE MOLECULE DRUGS DEVELOPED FOR CANCER AND OTHER INDICATIONS
David Mccormick · IIT Research Institute · funded by National Institutes of Health
2022–2025 · contract · N01
PRECLINICAL TOXICOLOGY OF LARGE MOLECULE DRUGS DEVELOPED FOR CANCER AND OTHER AND OTHER INDICATIONS INDICATIONS
David L. Mccormick · IIT Research Institute · funded by National Institutes of Health
2022–2026 · contract · N01
PRECLINICAL TOXICOLOGY OF LARGE MOLECULE DRUGS DEVELOPED FOR CANCER AND OTHER AND OTHER INDICATIONS INDICATIONS
David L. Mccormick · IIT Research Institute · funded by National Institutes of Health
2021–2023 · contract · N01
EVALUATION OF AFPEP FOR THE PREVENTION OF BREAST CANCER
David Mccormick · IIT Research Institute · funded by National Institutes of Health
2021 · contract · N01
CONTRACT KICK-OFF MEETING FOR NINDS PHARMACOLOGY AND TOXICOLOGY FOR THERAPEUTICS PROGRAM (PTTP)
Thomas Horn · IIT Research Institute · funded by National Institutes of Health
2020–2021 · contract · N01
PREVENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS; TASK ORDER TITLE: PRECLINICAL DEVELOPMENT OF AN RNA VACCINE FOR IMMUNOPREV
David Mccormick · IIT Research Institute · funded by National Institutes of Health
2020–2024 · contract · N01
NON-CLINICAL SAFETY ASSESSMENT OF DRINABANT, A CANNABINOID RECEPTOR (CB-1) ANTAGONIST, FOR ACUTE CANNABINOID OVERDOSE (ACO)
Thomas Horn · IIT Research Institute · funded by National Institutes of Health
2020–2023 · contract · N01
PREVENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS; TASK ORDER TITLE: PRECLINICAL DEVELOPMENT OF AN RNA VACCINE FOR IMMUNOPREV
David Mccormick · IIT Research Institute · funded by National Institutes of Health
2020–2024 · contract · N01
NON-CLINICAL SAFETY OF PTH-IA, INVERSE AGONIST, TO SUPPORT JANSEN METAPHYSEAL CHONDRODYSPLASIA (JMC) DISEASE.
Thomas Horn · IIT Research Institute · funded by National Institutes of Health
2020–2023 · contract · N01
TASK ORDER: TOPICAL RESATORVID FOR NONMELANOMA SKIN CANCER PREVENTIONPERIOD OF PERFORMANCE: 09/21/2020 - 03/31/2023
David Mccormick · IIT Research Institute · funded by National Institutes of Health
2020–2022 · contract · N01
TASK ORDER: TOPICAL RESATORVID FOR NONMELANOMA SKIN CANCER PREVENTIONPERIOD OF PERFORMANCE: 09/21/2020 - 03/20/2022
David Mccormick · IIT Research Institute · funded by National Institutes of Health
2020–2021 · contract · N01
SUPPORT FOR THE PRECLINICAL DEVELOPMENT OF EIF4A INHIBITORS ROCAGLAMIDE AND DIDESMETHYLROCAGLAMIDE. (TOXICIOLOGY SERVICES TO SUPPORT PRECLINICAL DRUG
David Mccormick · IIT Research Institute · funded by National Institutes of Health
2020–2025 · contract · N01
PREVENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS; TASK ORDER TITLE: PRECLINICAL DEVELOPMENT OF AN RNA VACCINE FOR IMMUNOPREV
David Mccormick · IIT Research Institute · funded by National Institutes of Health
2020–2022 · contract · N01
TASK ORDER: TOPICAL RESATORVID FOR NONMELANOMA SKIN CANCER PREVENTIONPERIOD OF PERFORMANCE: 09/21/2020 - 03/31/2023
David Mccormick · IIT Research Institute · funded by National Institutes of Health
2020–2021 · contract · N01
COVID-19 RELATED STUDY INVOLVING DOGS
David Mccormick · IIT Research Institute · funded by National Institutes of Health
2020–2024 · contract · N01
NON-CLINICAL SAFETY OF PTH-IA, INVERSE AGONIST, TO SUPPORT JANSEN METAPHYSEAL CHONDRODYSPLASIA (JMC) DISEASE.
Thomas Horn · IIT Research Institute · funded by National Institutes of Health
2019 · contract · N01
"CONTRACT ORIENTATION AND KICKOFF MEETING", TASK ORDER #1 UNDER 75N91019D00012. TASK ORDER PERIOD OF PERFORMANCE: 1/25/2019-2/24/2019.
David Mccormick · IIT Research Institute · funded by National Institutes of Health
2019 · contract · N01
BASE IDIQ CONTRACT FOR "PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: TOXICOLOGY AND PHARMACOLOGY TESTING"; POP: 1/25/2019-1/24/2024.
David Mccormick · IIT Research Institute · funded by National Institutes of Health
2018–2021 · contract · N01
LFA-9 (mPGES-1/5-LOX Inhibitor): Preclinical Studies to Support a Clinical Trial,
David Mccormick · IIT Research Institute · funded by National Institutes of Health
2018–2020 · contract · N01
LFA-9 (mPGES-1/5-LOX Inhibitor): Preclinical Studies to Support a Clinical Trial, POP 9/17/18-9/16/2020
David Mccormick · IIT Research Institute · funded by National Institutes of Health
2018–2024 · contract · N01
LFA-9 (mPGES-1/5-LOX Inhibitor): Preclinical Studies to Support a Clinical Trial,
David Mccormick · IIT Research Institute · funded by National Institutes of Health
2018–2021 · contract · N01
Preclinical Efficacy Evaluation of the Lipid-Based SMEDDS Formulation of DIM, BR-9001,
David Mccormick · IIT Research Institute · funded by National Institutes of Health
2018–2025 · contract · N01
Task F01: Non-clinical Services for Development of Interventional Agents for Infectious Diseases
Rebecca Linnell · IIT Research Institute · funded by National Institutes of Health
2018–2021 · contract · N01
Three Rabbit Study: (1) Dose Range Finding Study in Rabbits via Oral Gavage (Non-GLP); (2) Preliminary Embryo Fetal Developmental Study in Rabbits via Oral Gavage (Non-GLP); (3) Embryo Fetal Developme
(Contact) · IIT Research Institute · funded by National Institutes of Health
2018–2025 · contract · N01
Task D8: Nonclinical Services for Interventional Agents against SARS-CoV-2
William Johnson · IIT Research Institute · funded by National Institutes of Health